References
- Alkhatib NS, Erstad B, Ramos K, et al. Pricing methods in outcome-based contracting-δ1: cost-effectiveness analysis and cost utility analysis-based pricing. J Med Econ. 2020;23(11):1215–1222.
- Alkhatib NS, Ramos K, Erstad B, et al. Pricing methods in outcome-based contracting-δ2: willingness-to-pay-based pricing. J Med Econ. 2020;23(11):1223–1229.
- Alkhatib NS, Erstad B, Ramos K, et al. Pricing methods in outcome-based contracting-δ3: reference-based pricing. J Med Econ. 2020;23(11):1230–1236.
- Alkhatib NS, Bhattacharjee S, McBride A, et al. Pricing methods in outcome-based contracting-δ4: safety-based pricing. J Med Econ. 2020;23(11):1237–1245.
- Alkhatib NS, McBride A, Bhattacharjee S, et al. Pricing methods in outcome-based contracting-δ5: risk of efficacy failure-based pricing. J Med Econ. 2020;23(11):1246–1255.
- Pagliarulo N. Biogen inks outcomes-based contract for MS meds. [accessed December 2019]. Available from: https://www.biopharmadive.com/news/biogen-outcomes-based-contract-prime-multiple-sclerosis/512422/
- DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794–811.
- World Health Organization. Adherence to long-term therapies. [accessed December 2019]. Available from: https://www.who.int/chp/knowledge/publications/adherence_report/en/
- Duhig AM, Saha S, Smith S, et al. The current status of outcomes-based contracting for manufacturers and payers: an AMCP membership survey. J Manag Care Spec Pharm. 2018;24:410–415.
- Malmström RE, Godman BB, Diogene E, et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:39.
- Simoens S, Sinnaeve PR. Patient co-payment and adherence to statins: a review and case studies. Cardiovasc Drugs Ther. 2014;28:99–109.
- Chin AL, Bentley JP, Pollom EL. The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer. Cancer. 2019;125:374–381.
- Ferrario A, Arāja D, Bochenek T, et al. The implementation of managed entry agreements in Central and Eastern Europe: findings and implications. Pharmacoeconomics. 2017;35:1271–1285.
- U.S. Bureau of Labor Statistics. Prescription drugs in U.S. city average, all urban consumers, seasonally adjusted. [accessed December 2019]. Available from: https://data.bls.gov/timeseries/CUSR0000SEMF01?output_view=pct_3mths
- Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York (NY): Oxford University Press; 2011.
- RedBook Online [subscription database onlie]. Greenwood Village (CO): Truven Health Analytics. [accessed December 2019; updated periodically]. Available from: http://micromedex.com/products/product-suites/clinical-knowledge/redbook
- Soria J, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113–125.
- American Cancer Society. Chronic lymphocytic leukemia (CLL). [accessed December 2019]. Available from: https://www.cancer.org/cancer/chronic-lymphocytic-leukemia.html
- Krikorian S, Pories S, Tataronis G, et al. Adherence to oral chemotherapy: challenges and opportunities. J Oncol Pharm Pract. 2019;25:1590–1598.
- Muluneh B, Schneider M, Faso A, et al. Improved adherence rates and clinical outcomes of an integrated, closed-loop, pharmacist-led oral chemotherapy management program. J Oncol Pract. 2018;14:e324–e334.